KHN922 not checked

Chengdu Kanghong Biotech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens,intravenous (IV) administration every three weeks (D1) .”In the company’s words, NCT07514975 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors Cancer
Main trialPhase 1/2
“A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors”In the company’s words, NCT07514975 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumors Cancer

All 2438 drugs for Advanced Solid Tumors Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting Apr 2028 First-In-Human Study of KHN922 for Injection
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KHN922

Following is part of Solo: you see every change to KHN922 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in